Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12997234 | 0.96 | CYP3A4 (0.32) | CYP3A4THRB | |
| SCHEMBL28933423 | 0.96 | CYP3A4 (0.32) | CYP3A4THRB | |
| SCHEMBL12997235 | 0.96 | CYP3A4 (0.32) | CYP3A4THRB | |
| SCHEMBL942034 | 0.89 | CYP3A4 (0.32) | CYP3A4 | |
| SCHEMBL28553600 | 0.88 | ALDH1A1 (0.37) | HTT | |
| SCHEMBL1984877 | 0.88 | CYP3A4 (0.40) | CYP3A4HTT | |
| SCHEMBL2223021 | 0.86 | CYP3A4 (0.48) | CYP3A4THRBHTTMEN1CYP1A2 | |
| SCHEMBL28773268 | 0.85 | — | — | |
| SCHEMBL28553598 | 0.84 | ALDH1A1 (0.41) | THRBHTTMEN1KMT2A | |
| SCHEMBL28968784 | 0.84 | TLR2 (0.31) | LMNAMEN1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112375004-B | Preparation method of 2- (2-aminoethoxy) -1, 1-dimethoxyethane | 南京法恩化学有限公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-112375004-A | Preparation method of 2- (2-aminoethoxy) -1, 1-dimethoxyethane | 南京法恩化学有限公司 | 2021-02-19 | — | — | CN | disclosed |
| EP-2114158-B1 | 3-SUBSTITUTED-[1,2,3]BENZOTRIAZINONE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMA INC (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20100041647-A1 | 3-Substituted-[1,2,3]-Benzotriazinone compounds for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041647-A1 | 3-Substituted-[1,2,3]-Benzotriazinone compounds for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041647-A1 | 3-Substituted-[1,2,3]-Benzotriazinone compounds for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| EP-2114158-A1 | 3-SUBSTITUTED-[1,2,3]BENZOTRIAZINONE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008085505-A1 | 3-SUBSTITUTED-[1,2,3]BENZOTRIAZINONE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041647-A1 | 3-Substituted-[1,2,3]-Benzotriazinone compounds for enhancing glutamatergic synaptic responses | GRIN1, GRIN3B, GABRE | CYP3A4 4625/4885THRB 1350/4885LMNA 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.